Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure-Reference-Cited by-同舟云学术

Core‐binding factor acute myeloid leukemia with inv(16): Older age and high white blood cell count are risk factors for treatment failure

Published:2020-09-14 Issue:1 Volume:43 Page:
ISSN:1751-5521
Container-title:International Journal of Laboratory Hematology
language:en
Short-container-title:Int J Lab Hem

Author:

Ustun Celalettin¹²^ORCID,Morgan Elizabeth A.³^ORCID,Ritz Ethan M⁴,Vestergaard Hanne⁵,Pullarkat Sheeja⁶,Kluin Philip M.⁷,Ohgami Robert⁸,Baughn Linda B.⁹,Kim Young¹⁰,Ku Nam K.⁶,Czuchlewski David¹¹,Boe Møller Michael⁵¹²¹³,Schiefer Ana‐Iris¹⁴,Mrózek Krzysztof¹⁵,Horny Hans‐Peter¹⁶,George Tracy I.¹¹¹⁷^ORCID,Kielsgaard Kristensen Thomas¹²¹³,Beck Todd⁴,Nathan Sunita¹,Arana Yi Cecilia¹¹,Yeung Cecilia¹⁸¹⁹,Pullarkat Vinod²⁰^ORCID,Gotlib Jason²¹,Akin Cem²²,Kohlschmidt Jessica¹⁵²³,Salhotra Amandeep¹⁰,Soma Lori¹⁹^ORCID,Chen Dong⁹,Han Se Y.²,Cho Christina²⁴²⁵,Sperr Wolfgang²⁶^ORCID,Broesby‐Olsen Sigurd¹³²⁷,Linden Michael A.²⁸,Dolan Michelle²⁸,Hoermann Gregor²⁹,Hornick Jason L³^ORCID,Bloomfield Clara¹⁵,Nakamura Ryo²⁰,Joachim Deeg H.¹⁸¹⁹,Litzow Mark R.³⁰^ORCID,Borthakur Gautam³¹^ORCID,Weisdorf Daniel²,Huls Gerwin³²,Perales Miguel‐Angel²⁵,Valent Peter²⁶,Marcucci Guido²⁰

Affiliation:

1. Division of Hematology, Oncology and Cellular Therapy Rush University Chicago IL USA

2. Division of Hematology, Oncology and Transplantation Department of Medicine University of Minnesota Minneapolis MN USA

3. Department of Pathology Brigham and Women's Hospital Harvard Medical School Boston MA USA

4. Rush Bioinformatics and Biostatistics Core Rush University Chicago IL USA

5. Department of Hematology Odense University Hospital Odense Denmark

6. Department of Pathology University of California Los Angeles CA USA

7. Department of Pathology and Medical Biology University Medical Center Groningen University of Groningen Groningen The Netherlands

8. Department of Pathology Stanford University Stanford CA USA

9. Department of Laboratory Medicine and Pathology Mayo Clinic Rochester MN USA

10. Department of Pathology City of Hope National Medical Center Duarte CA USA

11. Department of Pathology University of New Mexico Albuquerque NM USA

12. Department of Pathology Odense University Hospital Odense Denmark

13. Mastocytosis Center Odense University Hospital Odense Denmark

14. Department of Pathology Medical University of Vienna Vienna Austria

15. The Ohio State University Comprehensive Cancer Center Columbus OH USA

16. Institute of Pathology Ludwig‐Maximilians‐University Munich Germany

17. Department of Pathology University of Utah Salt Lake City UT USA

18. Fred Hutchinson Cancer Research Center Seattle, WA USA

19. University of Washington School of Medicine Seattle WA USA

20. Division of Hematology and HCT City of Hope Duarte CA USA

21. Stanford Cancer Institute School of Medicine Stanford University Stanford CA USA

22. Division of Allergy and Clinical Immunology University of Michigan Ann Arbor MI USA

23. Alliance Statistics and Data Center The Ohio State University Comprehensive Cancer Center Columbus OH USA

24. Department of Medicine Adult Bone Marrow Transplant Service Memorial Sloan Kettering Cancer Center New York NY USA

25. Department of Medicine Weill Cornell Medical College New York NY USA

26. Department of Internal Medicine I Division of Hematology & Hemostaseology and Ludwig Boltzmann Institute for Hematology and Oncology Medical University of Vienna Vienna Austria

27. Department of Dermatology and Allergy Centre Odense Research Center for Anaphylaxis Odense Denmark

28. Department of Laboratory Medicine and Pathology University of Minnesota Minneapolis MN USA

29. Division of Medical and Chemical Laboratory Diagnostics ‐ Department of Laboratory Medicine Medical University of Vienna Vienna Austria

30. Department of Internal Medicine and Division of Hematology Mayo Clinic Rochester MN USA

31. Department of Leukemia University of Texas M.D. Anderson Cancer Center Houston TX USA

32. Department of Hematology University Medical Center Groningen University of Groningen Groningen The Netherlands

Publisher

Wiley

Subject

Biochemistry (medical),Clinical Biochemistry,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijlh.13338

Reference13 articles.

1. Emerging diagnostic and therapeutic approaches in core binding factor acute myeloid leukaemia

2. Prognostic Factors and Outcome of Core Binding Factor Acute Myeloid Leukemia Patients With t(8;21) Differ From Those of Patients With inv(16): A Cancer and Leukemia Group B Study

3. Individual Patient Data–Based Meta-Analysis of Patients Aged 16 to 60 Years With Core Binding Factor Acute Myeloid Leukemia: A Survey of the German Acute Myeloid Leukemia Intergroup

4. Comprehensive mutational profiling of core binding factor acute myeloid leukemia

5. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcome and prognostic factors of CBF pediatric AML patients with t(8;21) differ from patients with inv(16);BMC Cancer;2023-05-25

2. Comprehensive analysis for cellular senescence-related immunogenic characteristics and immunotherapy prediction of acute myeloid leukemia;Frontiers in Pharmacology;2022-09-26

3. Targeting miR-126 in inv(16) acute myeloid leukemia inhibits leukemia development and leukemia stem cell maintenance;Nature Communications;2021-10-22

4. How to Improve Prognostication in Acute Myeloid Leukemia with CBFB-MYH11 Fusion Transcript: Focus on the Role of Molecular Measurable Residual Disease (MRD) Monitoring;Biomedicines;2021-08-03

5. Emerging therapies for inv(16) AML;Blood;2021-05-13